Methods of detecting glycosaminoglycans

US10317376B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10317376-B2
Application numberUS-201314391775-A
CountryUS
Kind codeB2
Filing dateApr 11, 2013
Priority dateApr 11, 2012
Publication dateJun 11, 2019
Grant dateJun 11, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

In one aspect, the disclosure provides methods of distinguishing a glycosaminoglycan from one or more other components in a sample by subjecting the sample to size-exclusion chromatography using a mobile phase having a pH of 6.8 or lower. A mobile phase having a pH of 6.8 or lower is found to improve the separation of glycosaminoglycans from proteins during size exclusion chromatography. In some embodiments, improved separation is due to the low pH of the mobile phase causing elution of less dispersed fractions of the protein and/or glycosaminoglycan. In some embodiments, the overlap between protein and/or glycosaminoglycan fractions is reduced.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of separating a factor VIII (FVIII) protein or a factor IX (FIX) protein from glycosaminoglycan during chromatography, the method comprising: (i) subjecting a sample comprising one or more the FVIII or FIX proteins and glycosaminoglycan to a size-exclusion chromatography using a mobile phase having a pH of less than 3.0, and (ii) collecting a mobile phase fraction comprising the FVIII or FIX proteins; wherein the mobile phase comprises a salt; wherein the mobile phase fraction does not include the glycosaminoglycan or includes only small amounts of the glycosaminoglycan, and wherein the method does not include a use of fluorescent labeling. 2. The method of claim 1 , further comprising using a detection device to determine the amount of glycosaminoglycan in the mobile phase fraction. 3. The method of claim 2 , further comprising determining if the amount of glycosaminoglycan in the sample is above a threshold level. 4. The method of claim 3 , wherein the threshold level is 2 microgram/ml. 5. The method of claim 2 , wherein the detection device is a UV detector. 6. The method of claim 1 , wherein the sample is unpurified or partially purified. 7. The method of claim 1 , wherein the sample comprises a FVIII protein. 8. The method of claim 1 , wherein the sample comprises a FIX protein. 9. The method of claim 1 , wherein the glycosaminoglycan is negatively charged. 10. The method of claim 1 , wherein the glycosaminoglycan is dextran sulfate or heparin sulfate. 11. The method of claim 10 , wherein the glycosaminoglycan is dextran sulfate having a size of 6-8 kDa. 12. The method of claim 1 , wherein the size-exclusion chromatography packing material and mobile phase allow for secondary interactions. 13. The method of claim 12 , wherein the size-exclusion chromatography packing material is silica-based, has a pore size of between 100-200 Angstrom, and a particle size of 5 microns or less. 14. The method of claim 1 , wherein the size-exclusion chromatography is performed on a silica-based size-exclusion column. 15. The method of claim 1 , wherein the pH of the mobile phase is about 2.5. 16. The method of claim 15 , wherein the pH of the mobile phase is 2.5. 17. The method of claim 1 , wherein the salt is 200 mM NaCl. 18. The method of claim 1 , wherein the FVIII protein is Factor VIIIFc. 19. The method of claim 1 , wherein the FIX protein is Factor IXFc.

Assignees

Inventors

Classifications

  • Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran · CPC title

  • Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides · CPC title

  • Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins · CPC title

  • General processes for their isolation or fractionation, e.g. purification or extraction from biomass · CPC title

  • Liquid chromatography · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10317376B2 cover?
In one aspect, the disclosure provides methods of distinguishing a glycosaminoglycan from one or more other components in a sample by subjecting the sample to size-exclusion chromatography using a mobile phase having a pH of 6.8 or lower. A mobile phase having a pH of 6.8 or lower is found to improve the separation of glycosaminoglycans from proteins during size exclusion chromatography. In som…
Who is the assignee on this patent?
Bioverativ Therapeutics Inc
What technology area does this patent fall under?
Primary CPC classification C08B37/0003. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).